GETVV yields 90.09% · PFE yields 6.13%● Live data
📍 GETVV pulled ahead of the other in Year 1
Combined, GETVV + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GETVV + PFE for your $10,000?
Getnet Adquirência e Serviços Para Meios de Pagamento S.A. operates in the acquiring and services market for means of payment regulated by the Council National Monetary Council and the Central Bank of Brazil. The company engages in the provision of accreditation services for commercial and service establishments for accepting credit and debit cards; capturing, transmission, and processing of data and information; management of payments and receipts made to establishments accredited to its network; and installation, uninstallation, monitoring, supply, maintenance, and leasing of equipment used in transaction capture networks. It also engages in the development and marketing or licensing of software; commercializing products or distributing services of companies that provide cadastral information; provision of technical, commercial, and logistic infrastructure services for the business related to the receipt of accounts from concessionaires, banks, and other collection documents; and issuing electronic money. The company was formerly known as Farthi Empreendimentos e Participações S.A. and changed its name to Getnet Adquirência e Serviços para Meios de Pagamento S.A. in August 2014. The company was founded in 2008 and is based in São Paulo, Brazil. Getnet Adquirência e Serviços para Meios de Pagamento S.A. operates as a subsidiary of Banco Santander (Brasil) S.A.
Full GETVV Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.